HIV status is a risk factor for worse COVID-19 outcomes, but it remains uncertain the extent to which antiretroviral therapy, viral load, and CD4 count can reduce that risk, according to a new flurry of research presented at IAS 2021.
Our quick summaries of breaking conference research include new study findings on injectable long-acting cabotegravir/rilpivirine and the latest on lenacapavir, a twice-yearly injectable medication in the pipeline.
The latest data on health complications among people living with HIV, including new findings on COVID-19 severity.
For the CDC's proposed updates to PrEP guidelines to be effective, clinicians will need to start talking about sexual health.
Our Newest Posts
July 29, 2021: Racial disparities in hospitalization rates; city-specific mortality demographics; effects of traditional risk factors vs. antiretrovirals on weight gain and cardiovascular risk.
Alisa Grigorovich, Ph.D., explains how her research and educational film can help home health care providers avoid discriminating against or stigmatizing older LGBTQ adults.
July 22, 2021: How HIV criminalization laws may reduce disclosure; anxiety and housing satisfaction; poor immune response to delayed ART; the U.S.'s HIV testing mountain.
As new data attest, there is no one-size-fits-all approach to getting people retained in care; an individualized approach is best, if the health care facility can manage it.
July 15, 2021: Mind existing drug interactions when switching ART; lamivudine dosing amidst renal impairment; HPV vaccination among MSM; cervical cancer screening for women with HIV.
Lessons From the AIDS Epidemic Can Eradicate COVID-19: Interview With Linda-Gail Bekker and Ingrid Katz
Activism, research, and lessons learned from the AIDS epidemic are saving lives during the COVID-19 pandemic. They can also help lead the world toward herd immunity.